RxDoctor Payments Data

Christina Drummond, MD

Hospice and Palliative Medicine · Fort Wayne, INNPI 1538168539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $397 and has fallen 93.2% since, to $27 in 2025.

$458in general payments, 2019–2025

Across 31 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$73
  • Shionogi Inc$52
  • Kyowa Kirin, Inc.$49
  • Eisai Inc.$42
  • Ipsen Biopharmaceuticals, Inc$38
  • Exelixis Inc.$31
  • plus $172 from 10 others

What the payments were for

  • Food & beverage$45599%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$458 in reported general payments places this provider in the 85th percentile of 32 hospice and palliative medicine providers in Indiana.

See all hospice and palliative medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$25,868
Medicare patients
70
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$8,787
Oxycodone Hcl72$1,386
Gabapentin92$1,201
Venlafaxine Hcl ErVenlafaxine Hcl19$1,148
Morphine Sulfate ErMorphine Sulfate24$1,019
Mirtazapine50$720
Ondansetron Hcl29$679
Hydroxyzine Hcl29$657
Olanzapine25$593
Pregabalin14$518
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$389
Duloxetine Hcl26$253
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$248
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$232
Prochlorperazine Maleate19$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$14$59325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 32 hospice and palliative medicine providers in Indiana.

Other hospice and palliative medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →